PSMA radioligand PET/CT has shown higher sensitivity (SE) and specificity (SP) than conventional imaging and other radiopharmaceuticals, including choline-based agents, in both primary staging and biochemical recurrence of intermediate-to-high-risk PCa [8,9,10,11,12]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.